Experimental protocol
"Cultured ES-2 ovarian cancer cells were resuspended at 1 × 107/ml and inoculated subcutaneously into the nude mouse armpit. When tumors reached 60 mm3, they were extracted, cut into pieces of about 2 mm3, and inoculated subcutaneously into the nude mouse armpit. When the tumors reached an average volume of about 100 mm3, the mice were randomly divided into five groups (n = 10). Groups 1–3 received intra-tumor injection of CB-LHRH’ twice daily at 12.5, 25 or 50 mg/kg.d, respectively. Group 4 received 2 mg/kg cisplatin, once every 3 days [43], and group 5 the same volume of PBS, administered twice daily.
Tumor volumes were assessed every 3 d as 0.5 × length × width2 (where length is the longest diameter across the tumor and width the corresponding perpendicular diameter as measured by calipers). On day 13, 4 h after the last dose, mice were sacrificed, and tumors excised and weighed; tumor growth inhibition rate was derived as (1-tumor weight treated/tumor weight control) × 100 %."
www.ncbi.nlm.nih.gov/pmc/articles/PMC4809036/
Doch selbst Disorazol Z AEZS-138 (Disorazol Z-D-Lys6-LHRH conjugate), hat bessere Wirksamkeit und ist effizienter in der präklinischen Phase. Dürfte die nächsten 2-3 Jahre in die Klinikphase gehen.
Zurück
